SCYNEXIS Presents New Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology
Portfolio Pulse from Benzinga Newsdesk
SCYNEXIS has presented new preclinical data on its second-generation antifungal, SCY-247, at the 11th Congress on Trends in Medical Mycology. The data, presented by Mahmoud Ghannoum, Ph.D, showed in vitro activity against a broad spectrum of fungal pathogens and dose-dependent tissue distribution in vivo.
October 24, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The presentation of promising preclinical data on SCY-247 could potentially boost investor confidence in SCYNEXIS.
The presentation of positive preclinical data is often a positive signal for biotech companies as it indicates progress in the development of their products. This could potentially lead to increased investor confidence in SCYNEXIS and a short-term increase in its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100